Surveillance of adverse events following immunization in China: Past, present, and future

被引:48
作者
Liu, Dawei [1 ]
Wu, Wendi [1 ,2 ]
Li, Keli [1 ]
Xu, Disha [1 ]
Ye, Jiakai [1 ]
Li, Li [1 ]
Wang, Huaqing [1 ]
机构
[1] Chinese Ctr Dis Control & Prevent, Natl Immunizat Program, Beijing 100050, Peoples R China
[2] Univ Tampere, Sch Hlth Sci, FI-33014 Tampere, Finland
关键词
Adverse events following immunization (AEFI); Surveillance; Vaccination; VACCINE SAFETY; POSTMARKETING SURVEILLANCE; VAERS;
D O I
10.1016/j.vaccine.2015.04.060
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Surveillance for adverse events following immunization (AEFI) is an important component of any national immunization program. In the People's Republic of China (China), a populous, middle-income country, development of an AEFI surveillance system began in 2005. In 2008, the AEFI surveillance system was implemented as a nationwide, online system and called the Chinese National AEFI Information System (CNAEFIS). Since then, CNAEFIS has provided useful, national-level data on vaccine safety. National AEFI surveillance guidelines were issued jointly by the Ministry of Health and the China Food and Drug Administration in 2010. This article reviews the development, status, and key aspects of the Chinese AEFI surveillance system, and describes challenges and future plans for vaccine safety assessment in China. (C) 2015 Published by Elsevier Ltd.
引用
收藏
页码:4041 / 4046
页数:6
相关论文
共 40 条
  • [21] Identification Methods for Adverse Reaction Following Immunization, 2008, ID METH ADV REACT FO, V60
  • [22] Reporting of adverse events following immunization in Australia
    Isaacs, D
    Lawrence, G
    Boyd, I
    Ronaldson, K
    McEwen, J
    [J]. JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2005, 41 (04) : 163 - 166
  • [23] Data mining in the US using the vaccine adverse event reporting system
    Iskander, John
    Pool, Vitali
    Zhou, Weigong
    English-Bullard, Roseanne
    [J]. DRUG SAFETY, 2006, 29 (05) : 375 - 384
  • [24] Safety of Influenza A (H1N1) Vaccine in Postmarketing Surveillance in China.
    Liang, Xiao-Feng
    Li, Li
    Liu, Da-Wei
    Li, Ke-Li
    Wu, Wen-Di
    Zhu, Bao-Ping
    Wang, Hua-Qing
    Luo, Hui-Ming
    Cao, Ling-Sheng
    Zheng, Jing-Shan
    Yin, Da-Peng
    Cao, Lei
    Wu, Bing-Bing
    Bao, Hong-Hong
    Xu, Di-Sha
    Yang, Wei-Zhong
    Wang, Yu
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (07) : 638 - 647
  • [25] Matthew Miller, 2002, NZMJ, V115, P1
  • [26] An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system
    Singleton, JA
    Lloyd, JC
    Mootrey, GT
    Salive, ME
    Chen, RT
    [J]. VACCINE, 1999, 17 (22) : 2908 - 2917
  • [27] Data mining for signals in spontaneous reporting databases: proceed with caution
    Stephenson, Wendy P.
    Hauben, Manfred
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 (04) : 359 - 365
  • [28] Building Clinical Data Groups for Electronic Medical Record in China
    Tu, Haibo
    Yu, Yingtao
    Yang, Peng
    Tang, Xuejun
    Hu, Jianping
    Rao, Keqin
    Pan, Feng
    Xu, Yongyong
    Liu, Danhong
    [J]. JOURNAL OF MEDICAL SYSTEMS, 2012, 36 (02) : 723 - 736
  • [29] Post-marketing surveillance of live-attenuated Japanese encephalitis vaccine safety in China
    Wang, Yali
    Dong, Duo
    Cheng, Gang
    Zuo, Shuyan
    Liu, Dawei
    Du, Xiaoxi
    [J]. VACCINE, 2014, 32 (44) : 5875 - 5879
  • [30] WenDi W, 2012, CHIN J VACCINES IMMU, V18, P385